12 results
To compare live birth rates among patients receiving cryo thawed embryo transfer after endometrial preparation with estrogen/progesterone substitution and patients receiving cryo thawed embryo transfer in a natural cycle.
- To evaluate the treatment efficiency by time to progression according to RECIST 1.1
To determine a safe dose combination of carboplatin-cyclophosphamide combined with atezolizumab fixed dose in advanced breast cancer and gynaecologic cancer (ovarian, cervical and endometrial cancer).
Part A: To acquire an optimal pharmacokinetic model of [68Ga]Ga-FAPI-46 by which simplified methods to quantify [68Ga]Ga-FAPI-46 PET signal will be validated. Part B: To determine the test-retest repeatability of the quantitative measurements (as…
Modified objectives after implementation of protocol amendment February 2017: Primary: 1. Validate the BRCA-like test* in predicting differential PFS with first line alkylating and platinum agents when compared to paclitaxel in TNBC Secondary: 1.…
This phase II/III controlled multicenter trial will investigate the ability of individualized chemotherapy to improve the objective response rate of *triple-negative* breast cancer (estrogen receptor and progesterone receptor-negative, no HER2…
The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET results in improved efficacy while minimizing treatment toxicity in advanced stage HL patients treated with BV-containing regimens, BrAVD and…
This study will investigates the effect of high dose alkylating chemotherapy compared to standard dose chemotherapy as part of a multimodality approach in patients with oligometastatic HRD positive and/or BRCA1/2 related breast cancer.
Primary objective: To evaluate progression-free survival
In this randomized study the primary objective is to demonstrate a clinical significant reduction of RTX retreatments in AAV patients receiving combination RTX with cyclophosphamide remission-induction therapy as compared to RTX alone.Secondary…
To investigate whether (neo)adjuvant systemic treatment of intensified alkylating chemotherapy with peripheral stem cell rescue (mini-CTC) compared to AC-CP chemotherapy followed by 1-year olaparib monotherapy substantially improves overall survival…
The objective of rEECur is to identify the optimum systemic anticancer regimen for recurrent and refractory Ewing sarcoma based on the balance between efficacy and toxicity.